Quarterly report pursuant to Section 13 or 15(d)

NON CONTROLLING INTEREST

NON CONTROLLING INTEREST

9 Months Ended

Sep. 30, 2024

NOTE 17 - NON-CONTROLLING INTEREST

On July 28, 2016, the Company formed BioCorRx Pharmaceuticals, Inc., a Nevada Corporation, for the purpose of developing certain business lines. In connection with the formation, the, the newly formed sub issued 24.2% ownership to current or former officers of the Company with the Company retaining 75.8%. From inception through December 31, 2017, there were no significant transactions. In 2018, BioCorRx Pharmaceuticals, Inc. began operations.

On October 31, 2020, the Company entered into a written management services agreement with Joseph DeSanto MD, Inc. (“Medical Corporation”) under which the Company provides management and other administrative services to the Medical Corporation. These services include billing, collection of accounts receivable, accounting, management and human resource functions. Pursuant to the management services agreement, a management fee equal to 65% of the Medical Corporation’s gross collected monthly revenue. Through this arrangement, the Company is directing the activities that most significantly impact the financial results of the respective Medical Corporation; however, all clinical treatment decisions are made solely by licensed healthcare professionals. The Company has determined that it is the primary beneficiary, and, therefore, has consolidated the Medical Corporation as variable interest entity (“VIE”). The medical corporation: (i) had not yet generated any revenues and (ii) had no significant assets or liabilities since inception through September 30, 2024.

A reconciliation of the BioCorRx Pharmaceuticals, Inc. and Joseph DeSanto MD, Inc. non-controlling loss attributable to the Company:

Net loss attributable to the non-controlling interest for the three months ended September 30, 2024:

	BioCorRx Pharmaceuticals, Inc.			Joseph DeSanto MD
Net loss	$	(106,233	)	$	244
Average Non-controlling interest percentage of profit/losses		24.2	%		35.0	%
Net loss attributable to the non-controlling interest	$	(25,708	)	$	85

Net loss attributable to the non-controlling interest for the three months ended September 30, 2023:

	BioCorRx Pharmaceuticals, Inc.			Joseph DeSanto MD
Net loss	$	(2,397	)	$	(1,395	)
Average Non-controlling interest percentage of profit/losses		24.2	%		35.0	%
Net loss attributable to the non-controlling interest	$	(580	)	$	(488	)

Net loss attributable to the non-controlling interest for the nine months ended September 30, 2024:

	BioCorRx Pharmaceuticals, Inc.			Joseph DeSanto MD
Net loss	$	(175,033	)	$	(1,720	)
Average Non-controlling interest percentage of profit/losses		24.2	%		35.0	%
Net loss attributable to the non-controlling interest	$	(42,358	)	$	(602	)

Net loss attributable to the non-controlling interest for the nine months ended September 30, 2023:

	BioCorRx Pharmaceuticals, Inc.			Joseph DeSanto MD
Net loss	$	(5,692	)	$	(4,945	)
Average Non-controlling interest percentage of profit/losses		24.2	%		35.0	%
Net loss attributable to the non-controlling interest	$	(1,378	)	$	(1,730	)

The following table summarizes the changes in non-controlling interest for the nine months ended September 30, 2024:

Balance, December 31, 2023	$	(128,834	)
Net loss attributable to the non-controlling interest		(42,960	)
Balance, September 30, 2024		(171,794	)

The following table summarizes the changes in non-controlling interest for the nine months ended September 30, 2023:

Balance, December 31, 2022	$	(125,257	)
Net loss attributable to the non-controlling interest		(3,108	)
Balance, September 30, 2023		(128,365	)